Dose calculation, design and development of nateglinide matrix tablets using quality by design approach and its pharmacokinetic evaluation in animal model

被引：3
作者：
Betha S. [1 ,2 ]
Pamula Reddy B. [1 ]
Swamy P.V. [1 ]
Mohan Varma M. [1 ]
Basava Raju D. [1 ]
Kolapalli V.R.M. [2 ]
机构：
[1] Department of Pharmaceutical Technology, Shri Vishnu College of Pharmacy, Bhimavaram, 534202, Andhra Pradesh
[2] Department of Pharmaceutical Technology, AU College of Pharmaceutical Sciences, Andhra University, Vishakhapatnam
来源：
Journal of Pharmaceutical Investigation | 2015年 / 45卷 / 6期
关键词：
Central composite design; In vitro and in vivo Pharmacokinetic studies; Nateglinide sustained release matrix tablets; Response surface methodology;
D O I：
10.1007/s40005-015-0200-5
中图分类号：
学科分类号：
摘要：
The present work deals with design of zero order sustained release nateglinide matrix tablets by application of statistical design using response surface methodology as a tool. Central composite design was used to investigate the effect of two independent formulation variables (at three levels) such as Kollidon SR (X1), PVP K 30 (X2) on dependent variables viz. time required to release 30 % (T30, Y1), percentage drug released at 6th hour (DR6, Y2) and time required to release 90 % (T90, Y3) of drug. Wet granulation technique was employed for tablets preparation. The result showed that release pattern of the optimized formulation was almost equal to the statistically predicted values. There was no chemical interaction observed between drug and polymer based up on FTIR and DSC results. In vitro release studies were performed in 0.1 N HCl containing 0.5 % SLS for first 2 h followed by pH 6.8 phosphate buffer containing 0.5 % SLS. Stability studies were performed to statistically optimized formulation. The release pattern from statistically optimized formulation was followed zero order kinetics with non-Fickian process as drug release mechanism. Pharmacokinetic studies were performed to optimized formulation in comparison with nateglinide suspension in rabbit as animal model. The results of in vivo studies revealed the % relative bioavailability of statistically optimized formulation was found to be 68.87 %. © 2015, The Korean Society of Pharmaceutical Sciences and Technology.
引用
收藏
页码：515 / 528
页数：13
相关论文
共 29 条
  • [1] Ai M., Tanaka A., Ogita K., Shimokado K., Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes, Diabetes Care, 29, (2011)
  • [2] Bhupinder S., Kumar R., Naveen A., Optimizing drug delivery systems using systematic “Design of Experiments” Part I: fundamental aspects, Criti Rev Ther Drug, 22, 1, pp. 27-105, (2004)
  • [3] Brahmankar D.M., Biopharmaceutics and pharmacokinetics—a treatise, pp. 343-350, (2008)
  • [4] Chisato M., Nobutaka N., Hidetoshi S., Haruo O., Akira O., Akira Y., Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets, Chem Pharm Bull, 54, 4, pp. 409-414, (2006)
  • [5] Dunn C., Faulds D., Nateglinide, Drugs, 60, (2000)
  • [6] Ferreira S.L.C., Bruns R.E., Ferreira H.S., Matos G.D., David J.M., Brandao G.C., Box-Behnken design: an alternative for the optimization of analytical methods, Anal Chim Acta, 597, 2, pp. 179-186, (2007)
  • [7] Geoffroy J.M., Fredrickson J.K., Shelton J.T., A mixture experiment approach for controlling the dissolution rate of a sustained release tablet, Drug Dev Ind Pharm, 24, 9, pp. 799-806, (1998)
  • [8] Ghosh M.N., Fundamentals of experimental pharmacology, pp. 192-194, (2005)
  • [9] Gribble F.M., Manley S.E., Levy J.C., Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166), Diabetes Care, 24, 7, pp. 1221-1225, (2001)
  • [10] Grimm W., Extension of the International Conference on Harmonisation Tripartite Guidelines for stability testing of new drug substances and products to countries of Climatic Zones III and IV, Drug Dev Ind Pharm, 24, pp. 313-325, (1998)
123